{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:15:25Z","timestamp":1790392525422,"version":"4.1.0"},"reference-count":152,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants, young children, as well as elderly and immunocompromised patients worldwide. RSV is classified into two major subtypes, RSV-A and RSV-B, and remains the most frequently detected pathogen in infants hospitalized with acute respiratory infections. Recent advances have brought both passive and active immunization strategies, including FDA-approved vaccines for older adults and pregnant women and new monoclonal antibodies (mAbs) for infant protection. Although significant progress has been made, the need remains for improved antiviral treatments, particularly for vulnerable infants and immunocompromised patients. Recent studies have identified multiple RSV mutations that confer resistance to current treatments. These mutations, detected in both in vitro studies and clinical isolates, often complicate therapeutic outcomes, underscoring the need for updated and effective management strategies. In this context, evaluating protein flexibility through tools like DisoMine provides insight into how specific mutations impact structural dynamics at binding sites, thus affecting ligand affinity. This review aims to synthesize these aspects, offering a comprehensive insight into ongoing efforts to counteract RSV and address the evolving challenge of drug resistance.<\/jats:p>","DOI":"10.3390\/v17060793","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:22:41Z","timestamp":1748596961000},"page":"793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4659-0219","authenticated-orcid":false,"given":"Alessia","family":"Magnapera","sequence":"first","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-1366","authenticated-orcid":false,"given":"Anna","family":"Riccio","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6818-5325","authenticated-orcid":false,"given":"Antonio","family":"Curcio","sequence":"additional","affiliation":[{"name":"Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Tramontozzi","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0858","authenticated-orcid":false,"given":"Lorenzo","family":"Piermatteo","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9334-8582","authenticated-orcid":false,"given":"Stefano","family":"D\u2019Anna","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0437-358X","authenticated-orcid":false,"given":"Stefano","family":"Alcaro","sequence":"additional","affiliation":[{"name":"Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Alteri","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy"},{"name":"Microbiology and Virology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"La Frazia","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-7760","authenticated-orcid":false,"given":"Anna","family":"Artese","sequence":"additional","affiliation":[{"name":"Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2488-2082","authenticated-orcid":false,"given":"Romina","family":"Salpini","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Svicher","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/oxfordjournals.aje.a119901","article-title":"Recovery from infants with respiratory illness of a virus related to Chimpanzee Coryza Agent (CCA). I. Isolation, properties and characterization","volume":"66","author":"Chanock","year":"1957","journal-title":"Am. J. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Blount","year":"1956","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/20477724.2022.2038053","article-title":"Global distribution of Respiratory Syncytial Virus A and B infections: A Systematic Review","volume":"116","author":"Noyola","year":"2022","journal-title":"Pathog. Glob. Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/QCO.0000000000000952","article-title":"The disease burden of respiratory syncytial virus in Infants","volume":"36","author":"Munro","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11739-023-03438-x","article-title":"The global burden of lower respiratory infections attributable to respiratory syncytial virus in 204 countries and territories, 1990\u20132019: Findings from the Global Burden of Disease Study 2019","volume":"19","author":"Wu","year":"2024","journal-title":"Intern. Emerg. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Gatt, D., Martin, I., Alfouzan, R., and Moraes, T.J. (2023). Prevention and treatment strategies for Respiratory Syncytial Virus (RSV). Pathogens, 12.","DOI":"10.3390\/pathogens12020154"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to an RSV vaccine","volume":"125","author":"Mejias","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Killikelly, A.M., Kanekiyo, M., and Graham, B.S. (2016). Pre-fusion F is absent on the surface of formalin-inactivated Respiratory Syncytial Virus. Sci. Rep., 6.","DOI":"10.1038\/srep34108"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against Respiratory Syncytial Virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/d41586-023-01529-5","article-title":"\u201cA Good Day\u201d: FDA approves world\u2019s first RSV vaccine","volume":"617","year":"2023","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1016\/S2666-5247(23)00195-7","article-title":"First RSV vaccine approvals","volume":"4","author":"Venkatesan","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of the Pfizer Respiratory Syncytial Virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: Recommendations of the advisory committee on immunization practices\u2014United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_14","first-page":"487","article-title":"FDA approves mRNA-based RSV vaccine","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003495-199958020-00009","article-title":"Palivizumab","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1055\/a-1990-2633","article-title":"Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by Respiratory Syncytial Virus: A systematic review","volume":"41","author":"Gonzales","year":"2024","journal-title":"Am. J. Perinatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness for prevention of Respiratory Syncytial Virus\u2013associated hospitalization among infants entering their first Respiratory Syncytial Virus season\u2014New vaccine surveillance network, October 2023\u2013February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of Nirsevimab for the prevention of Respiratory Syncytial Virus disease among infants and young children: Recommendations of the advisory committee on immunization practices\u2014United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","article-title":"Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis","volume":"39","author":"Tejada","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.healun.2005.06.027","article-title":"Intravenous Ribavirin is a safe and cost-effective treatment for Respiratory Syncytial Virus infection after lung transplantation","volume":"24","author":"Glanville","year":"2005","journal-title":"J. Heart Lung Transpl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/acs.jmedchem.8b01361","article-title":"State of the art in Respiratory Syncytial Virus drug discovery and development","volume":"62","author":"Cockerill","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40121-020-00383-6","article-title":"The future of Respiratory Syncytial Virus disease prevention and treatment","volume":"10","author":"Domachowske","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11543","DOI":"10.1021\/acs.jmedchem.4c00630","article-title":"Recent progress toward the discovery of small molecules as novel anti-Respiratory Syncytial Virus agents","volume":"67","author":"Felicetti","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/infdis\/jiz059","article-title":"RESCEU Investigators. Global disease burden estimates of Respiratory Syncytial Virus-associated acute respiratory infection in older adults in 2015: A systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory Syncytial Virus: Infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/irv.12667","article-title":"Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden","volume":"14","author":"Pebody","year":"2020","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to Respiratory Syncytial Virus in young children in 2015: A systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41479-022-00098-x","article-title":"Estimated incidence of respiratory hospitalizations attributable to RSV infections across age and socioeconomic groups","volume":"14","author":"Zheng","year":"2022","journal-title":"Pneumonia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40266-024-01118-9","article-title":"Respiratory Syncytial Virus Infection in Older Adults: An Update","volume":"41","author":"Alfano","year":"2024","journal-title":"Drugs Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory Syncytial Virus disease burden in adults aged 60\u2009years and older in high-income countries: A systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/infdis\/jiy056","article-title":"Respiratory Syncytial Virus seasonality: A global overview","volume":"217","author":"Sly","year":"2018","journal-title":"J. Inf. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","article-title":"Seasonality of Respiratory Syncytial Virus\u2014United States, 2017\u20132023","volume":"72","author":"Hamid","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(22)00525-4","article-title":"Epidemiology of Respiratory Syncytial Virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: A retrospective observational study","volume":"23","author":"Bardsley","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_34","first-page":"107231","article-title":"Seasonality and severity of Respiratory Syncytial Virus during the COVID-19 Pandemic: A dynamic cohort study","volume":"148","author":"Lastrucci","year":"2024","journal-title":"J. Inf. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102089","DOI":"10.1016\/j.eclinm.2023.102089","article-title":"Why Has the Epidemiology of RSV Changed during the COVID-19 pandemic?","volume":"61","author":"Reicherz","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yu, J.M., Fu, Y.H., Peng, X.L., and Zheng, Y.P. (2021). Genetic diversity and molecular evolution of human Respiratory Syncytial Virus A and B. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-92435-1"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Escalante, J.C., Comas-Garc\u00eda, A., Bernal-Silva, S., and Noyola, D.E. (2021). Respiratory Syncytial Virus B sequence analysis reveals a novel early genotype. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-83079-2"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/INF.0b013e318282603a","article-title":"Distribution of Respiratory Syncytial Virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea","volume":"32","author":"Jafri","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","article-title":"Respiratory Syncytial Virus Entry and how to block it","volume":"17","author":"Battles","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/mBio.01554-18","article-title":"The Structure of the Human Respiratory Syncytial Virus M2-1 Protein Bound to the Interaction Domain of the Phosphoprotein P Defines the Orientation of the Complex","volume":"9","author":"Selvaraj","year":"2018","journal-title":"mBio"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Scudero, O.B., Santiago, V.F., Palmisano, G., Simabuco, F.M., and Ventura, A.M. (2023). The respiratory syncytial virus M2-2 protein is targeted for proteasome degradation and inhibits translation and stress granules assembly. PLoS ONE, 18.","DOI":"10.1101\/2023.01.02.522538"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41579-023-00919-w","article-title":"Respiratory Syncytial Virus infection and novel interventions","volume":"21","author":"Langedijk","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_43","first-page":"3","article-title":"Respiratory Syncytial Virus: Virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/JVI.00256-14","article-title":"Structural Analysis of Respiratory Syncytial Virus Reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex","volume":"88","author":"Kiss","year":"2014","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Okura, T., Takahashi, T., Kameya, T., Mizukoshi, F., Nakai, Y., Kakizaki, M., Nishi, M., Otsuki, N., Kimura, H., and Miyakawa, K. (2024). MARCH8 Restricts RSV Replication by Promoting Cellular Apoptosis Through Ubiquitin-Mediated Proteolysis of Viral SH Protein. Viruses, 16.","DOI":"10.3390\/v16121935"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e00095","DOI":"10.1128\/JVI.00095-21","article-title":"CX3CR1 engagement by Respiratory Syncytial Virus leads to induction of nucleolin and dysregulation of cilium-related genes","volume":"95","author":"Anderson","year":"2021","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1128\/JVI.74.14.6442-6447.2000","article-title":"The fusion glycoprotein of human Respiratory Syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate","volume":"74","author":"Feldman","year":"2000","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41586-020-2369-7","article-title":"IGF1R is an entry receptor for Respiratory Syncytial Virus","volume":"583","author":"Griffiths","year":"2020","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10508","DOI":"10.1128\/JVI.74.22.10508-10513.2000","article-title":"Glycosaminoglycan sulfation requirements for Respiratory Syncytial Virus infection","volume":"74","author":"Hallak","year":"2000","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lingemann, M., Mccarty, T., Liu, X., Buchholz Id, U.J., Surman, S., Martin, S.E., Collins, P.L., and Munir Id, S. (2019). The alpha-1 subunit of the Na+, K+-ATPase (ATP1A1) is required for macropinocytic entry of Respiratory Syncytial Virus (RSV) in human respiratory epithelial cells. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007963"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm.2444","article-title":"Identification of nucleolin as a cellular receptor for human Respiratory Syncytial Virus","volume":"17","author":"Tayyari","year":"2011","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Feng, Z., Xu, L., and Xie, Z. (2022). Receptors for Respiratory Syncytial Virus infection and host factors regulating the life cycle of Respiratory Syncytial Virus. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.858629"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1128\/JVI.75.15.6825-6834.2001","article-title":"Functional analysis of recombinant Respiratory Syncytial Virus deletion mutants lacking the small hydrophobic and\/or attachment glycoprotein gene","volume":"75","author":"Techaarpornkul","year":"2001","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7788","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of Respiratory Syncytial Virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/90675","article-title":"CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein","volume":"8","author":"Tripp","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Johnson, S.M., McNally, B.A., Ioannidis, I., Flano, E., Teng, M.N., Oomens, A.G., Walsh, E.E., and Peeples, M.E. (2015). Respiratory Syncytial Virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005318"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbagen.2019.05.012","article-title":"Exploitation of glycosylation in enveloped virus pathobiology","volume":"1863","author":"Watanabe","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"31","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_59","first-page":"7","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"14","author":"Ngwuta","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1096\/fj.201800579R","article-title":"Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane","volume":"33","author":"Tang","year":"2019","journal-title":"FASEB J."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Piacentini, S., La Frazia, S., Riccio, A., Pedersen, J.Z., Topai, A., Nicolotti, O., Rossignol, J.F., and Santoro, M.G. (2018). Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: Role of glycoprotein-specific thiol oxidoreductase ERp57. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-28172-9"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciz100","article-title":"Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness","volume":"69","author":"Guerrero","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Piacentini, S., Riccio, A., Santopolo, S., Pauciullo, S., La Frazia, S., Rossi, A., Rossignol, J.F., and Santoro, M.G. (2023). The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: Effect on the viral spike glycoprotein. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1206951"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.1128\/JVI.00457-07","article-title":"Coupled translation of the second open reading frame of M2 mRNA is sequence dependent and differs significantly within the subfamily Pneumovirinae","volume":"81","author":"Gould","year":"2007","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1099\/vir.0.053025-0","article-title":"The Respiratory Syncytial Virus nucleoprotein-rna complex forms a left-handed helical nucleocapsid","volume":"94","author":"Bakker","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Blondot, M.-L., Dubosclard, V., Fix, J., Lassoued, S., Aumont-Nicaise, M., Bontems, F., El\u00e9ou\u00ebt, J.F., and Sizun, C. (2012). Structure and functional analysis of the RNA-and viral phosphoprotein-binding domain of Respiratory Syncytial Virus M2-1 protein. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002734"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1074\/mcp.M111.015909","article-title":"The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways","volume":"11","author":"Hastie","year":"2012","journal-title":"Mol. Cell. Proteom."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e2020587118","DOI":"10.1073\/pnas.2020587118","article-title":"Structural basis for IFN antagonism by human respiratory syncytial virus nonstructural protein 2","volume":"118","author":"Pei","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Thornhill, E.M., and Verhoeven, D. (2020). Respiratory syncytial virus\u2019s non-structural proteins: Masters of interference. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00225"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bbrc.2007.11.042","article-title":"The RSV F and G glycoproteins interact to form a complex on the surface of infected cells","volume":"366","author":"Low","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109985","DOI":"10.1016\/j.virol.2024.109985","article-title":"Evidence that an interaction between the respiratory syncytial virus F and G proteins at the distal ends of virus filaments mediates efficient multiple cycle infection","volume":"591","author":"Huong","year":"2024","journal-title":"Virology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"24671","DOI":"10.1074\/jbc.M111.332791","article-title":"The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels","volume":"287","author":"Gan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Van Royen, T., Rossey, I., Sedeyn, K., Schepens, B., and Saelens, X. (2022). How RSV Proteins Join Forces to Overcome the Host Innate Immune Response. Viruses, 14.","DOI":"10.3390\/v14020419"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1073\/pnas.94.25.13961","article-title":"Respiratory Syncytial Virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant","volume":"94","author":"Karron","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Krzyzaniak, M.A., Zumstein, M.T., Gerez, J.A., Picotti, P., and Helenius, A. (2013). Host cell entry of Respiratory Syncytial Virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003309"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41467-017-00655-9","article-title":"Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus","volume":"15","author":"Rincheval","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.virol.2015.01.014","article-title":"Initiation and regulation of paramyxovirus transcription and replication","volume":"479\u2013480","author":"Noton","year":"2015","journal-title":"Virology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory Syncytial Virus: From pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41467-017-00732-z","article-title":"RSV glycoprotein and genomic RNA dynamics reveal filament assembly prior to the plasma membrane","volume":"8","author":"Vanover","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.5694\/j.1326-5377.1961.tb70131.x","article-title":"A syncytial virus associated with epidemic disease of the lower respiratory tract in infants and young children","volume":"2","author":"Lewis","year":"1961","journal-title":"Med. J. Aust."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1038\/s41467-024-47421-2","article-title":"Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials","volume":"15","author":"Ahani","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiy189","article-title":"Prevalence and significance of substitutions in the fusion protein of Respiratory Syncytial Virus resulting in neutralization escape from antibody MEDI8897","volume":"218","author":"Zhu","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_83","unstructured":"National Center for Biotechnology Information (NCBI) [Internet] (2025, May 19). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information, Available online: https:\/\/www.ncbi.nlm.nih.gov\/."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","article-title":"PubChem 2025 update","volume":"53","author":"Kim","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_86","unstructured":"(2020). Schr\u00f6dinger Release 2020-4: Maestro, Schr\u00f6dinger LLC."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Orlando, G., Raimondi, D., Codic\u00e8, F., Tabaro, F., and Vranken, W. (2022). Prediction of disordered regions in proteins with recurrent neural networks and protein dynamics. J. Mol. Biol., 434.","DOI":"10.1016\/j.jmb.2022.167579"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9619","DOI":"10.1073\/pnas.1106536108","article-title":"Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers","volume":"108","author":"Swanson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.0910108106","article-title":"Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein","volume":"107","author":"Roymans","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.virusres.2019.04.006","article-title":"Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity","volume":"266","author":"Leemans","year":"2019","journal-title":"Virus Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/JVI.02472-14","article-title":"Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis","volume":"89","author":"Hotard","year":"2015","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-023-36459-3","article-title":"Cross-protective antibodies against common endemic respiratory viruses","volume":"14","author":"Rodarte","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1128\/jvi.47.1.171-177.1983","article-title":"Monoclonal antibodies to Respiratory Syncytial Virus proteins: Identification of the fusion protein","volume":"47","author":"Walsh","year":"1983","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Cur. Opin. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e20182308","DOI":"10.1542\/peds.2018-2308","article-title":"Monoclonal antibody treatment of RSV bronchiolitis in young infants: A randomized trial","volume":"143","author":"Alansari","year":"2019","journal-title":"Pediatrics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nsmb.1723","article-title":"Structural basis of respiratory syncytial virus neutralization by motavizumab","volume":"17","author":"McLellan","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/DHPS.S348727","article-title":"Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease","volume":"15","author":"Galway","year":"2023","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of Respiratory Syncytial Virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.01497-15","article-title":"GS-5806 inhibits a broad range of Respiratory Syncytial Virus clinical isolates by blocking the virus-cell fusion process","volume":"60","author":"Perron","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/infdis\/jiaa028","article-title":"Drug resistance assessment following administration of Respiratory Syncytial Virus (RSV) fusion inhibitor presatovir to participants experimentally infected with RSV","volume":"222","author":"Stray","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jir790","article-title":"Natural Polymorphisms and resistance-associated mutations in the fusion protein of Respiratory Syncytial Virus (RSV): Effects on RSV susceptibility to palivizumab","volume":"205","author":"Zhu","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_103","first-page":"127","article-title":"Neutralizing epitopes of RSV and palivizumab resistance in Japan","volume":"63","author":"Hashimoto","year":"2017","journal-title":"J. Med. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e0120521","DOI":"10.1128\/JVI.01205-21","article-title":"Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in Respiratory Syncytial Virus Fusion protein","volume":"95","author":"Tang","year":"2021","journal-title":"J. Virol."},{"key":"ref_105","first-page":"e1407","article-title":"Pharmacological characterization of TP0591816, a novel macrocyclic Respiratory Syncytial Virus fusion inhibitor with antiviral activity against F protein mutants","volume":"65","author":"Yoshida","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Rhodin, M.H.J., McAllister, N.V., Castillo, J., Noton, S.L., Fearns, R., Kim, I.J., Yu, J., Blaisdell, T.P., Panarese, J., and Shook, B.C. (2021). EDP-938, a novel nucleoprotein inhibitor of Respiratory Syncytial Virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009428"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Deval, J., Hong, J., Wang, G., Taylor, J., Smith, L.K., Fung, A., Stevens, S.K., Liu, H., Jin, Z., and Dyatkina, N. (2015). Molecular Basis for the selective inhibition of Respiratory Syncytial Virus RNA polymerase by 2\u2032-fluoro-4\u2032-chloromethyl-cytidine triphosphate. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004995"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1743-422X-4-71","article-title":"Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human Respiratory Syncytial Virus","volume":"4","author":"Liu","year":"2007","journal-title":"Virol. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"eaar3534","DOI":"10.1126\/sciimmunol.aar3534","article-title":"Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies","volume":"3","author":"Fedechkin","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.virol.2014.02.010","article-title":"Escape from neutralization by the Respiratory Syncytial Virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein","volume":"454\u2013455","author":"Bates","year":"2014","journal-title":"Virology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nchembio.1982","article-title":"Molecular mechanism of Respiratory Syncytial Virus fusion inhibitors","volume":"12","author":"Battles","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/cid\/ciz1166","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of Respiratory Syncytial Virus upper respiratory tract infection in hematopoietic-cell transplant recipients","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1021\/acs.jmedchem.0c00226","article-title":"Discovery of 3-({5-Chloro-1-[3-(methylsulfonylpropyl]-1 H-indol-2-Yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2 H-imidazo [4,5- c]pyridin-2-one (JNJ-53718678), a potent and orally bioavailable fusion inhibitor of Respiratory Syncytial Virus","volume":"63","author":"Vendeville","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of ziresovir as a potent, selective, and orally bioavailable Respiratory Syncytial Virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Song, Q., Zhu, H., Qiu, M., Cai, J., Hu, Y., Yang, H., Rao, S., Li, Y., Li, M., and Hu, L. (2024). A new mechanism of respiratory syncytial virus entry inhibition by small-molecule to overcome K394R-associated resistance. mBio, 15.","DOI":"10.1128\/mbio.01385-24"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","article-title":"Inhibition of Respiratory Syncytial Virus fusion by the small molecule VP-14637 via specific interactions with F protein","volume":"77","author":"Douglas","year":"2003","journal-title":"J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41467-017-02258-w","article-title":"Protein conformational flexibility modulates kinetics and thermodynamics of drug binding","volume":"8","author":"Amaral","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ijbiomac.2008.01.011","article-title":"Studies on flexibility and binding affinity of Asp25 of HIV-1 protease mutants","volume":"42","author":"Purohit","year":"2008","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"43268","DOI":"10.1074\/jbc.M303899200","article-title":"Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I","volume":"278","author":"Fiorani","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Amusengeri, A., Tata, R.B., and Tastan Bishop, \u00d6. (2020). Understanding the Pyrimethamine Drug Resistance Mechanism via Combined Molecular Dynamics and Dynamic Residue Network Analysis. Molecules, 25.","DOI":"10.3390\/molecules25040904"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/prot.24151","article-title":"Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors","volume":"80","author":"Braz","year":"2012","journal-title":"Proteins"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"W52","DOI":"10.1093\/nar\/gkab425","article-title":"B2bTools: Online predictions for protein biophysical features and their conservation","volume":"49","author":"Kagami","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1128\/JVI.00058-12","article-title":"Characterization of a viral phosphoprotein binding site on the surface of the Respiratory Syncytial nucleoprotein","volume":"86","author":"Galloux","year":"2012","journal-title":"J. Virol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Cao, D., Gao, Y., and Liang, B. (2021). Structural Insights into the Respiratory Syncytial Virus RNA Synthesis Complexes. Viruses, 13.","DOI":"10.3390\/v13050834"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.1177634","article-title":"Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of Respiratory Syncytial Virus","volume":"326","author":"Tawar","year":"2009","journal-title":"Science"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"11129","DOI":"10.1128\/JVI.01612-15","article-title":"A druggable pocket at the nucleocapsid\/phosphoprotein interaction site of human Respiratory Syncytial Virus","volume":"89","author":"Pereira","year":"2015","journal-title":"J. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"105948","DOI":"10.1016\/j.antiviral.2024.105948","article-title":"Direct-acting antivirals for RSV treatment, a review","volume":"229","author":"Bonneux","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Anderson, L.J., Jadhao, S.J., Paden, C.R., and Tong, S. (2021). Functional features of the Respiratory Syncytial Virus G protein. Viruses, 13.","DOI":"10.3390\/v13071214"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2217\/imt.10.53","article-title":"Therapeutic targeting of Respiratory Syncytial Virus G-protein","volume":"2","author":"Kauvar","year":"2010","journal-title":"Immunotherapy"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Borochova, K., Niespodziana, K., Hammar, K.S., van Hage, M., Hedlin, G., S\u00f6derh\u00e4ll, C., Focke-Tejkl, M., and Valenta, R. (2020). Features of the human antibody response against the Respiratory Syncytial Virus surface glycoprotein G. Vaccines, 8.","DOI":"10.3390\/vaccines8020337"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1099\/vir.0.000218","article-title":"CX3CR1 is an important surface molecule for Respiratory Syncytial Virus infection in human airway epithelial cells","volume":"96","author":"Chirkova","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1128\/JVI.73.8.6610-6617.1999","article-title":"Identification of a linear heparin binding domain for human Respiratory Syncytial Virus attachment glycoprotein G","volume":"73","author":"Feldman","year":"1999","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"12191","DOI":"10.1128\/JVI.01604-08","article-title":"The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes","volume":"82","author":"Bukreyev","year":"2008","journal-title":"J. Virol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2015.02.035","article-title":"An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB\/c mice","volume":"483","author":"Todd","year":"2015","journal-title":"Virology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1128\/JVI.00451-10","article-title":"Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in Respiratory Syncytial Virus (RSV)-challenged na\u00efve and formalin-inactivated RSV-immunized BALB\/c mice","volume":"84","author":"Radu","year":"2010","journal-title":"J. Virol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.antiviral.2018.04.014","article-title":"Anti-Respiratory Syncytial Virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB\/c mouse model","volume":"154","author":"Caidi","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/600108","article-title":"Therapeutic monoclonal antibody treatment targeting Respiratory Syncytial Virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB\/c mice","volume":"200","author":"Haynes","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Hikichi, Y., Burdick, R.C., Patro, S.C., Penrose, K.J., Clark, E., Ablan, S.D., Mellors, J.W., Parikh, U.M., Wu, X., and Pathak, V.K. (2025, January 9\u201312). Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs. Proceedings of the Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA. Abstract Number 155.","DOI":"10.1101\/2025.05.17.654662"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cell.2019.08.014","article-title":"Structure of the Respiratory Syncytial Virus polymerase complex","volume":"179","author":"Gilman","year":"2019","journal-title":"Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e00520-20","DOI":"10.1128\/JVI.00520-20","article-title":"The C-terminal domain of the Sudan Ebolavirus L protein is essential for RNA binding and methylation","volume":"94","author":"Valle","year":"2020","journal-title":"J. Virol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Sutto-Ortiz, P., El\u00e9ou\u00ebt, J.F., Ferron, F., and Decroly, E. (2023). Biochemistry of the Respiratory Syncytial Virus L protein embedding RNA polymerase and capping activities. Viruses, 15.","DOI":"10.3390\/v15020341"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-019-14246-3","article-title":"Cryo-EM structure of the Respiratory Syncytial Virus RNA polymerase","volume":"11","author":"Cao","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Yu, X., Abeywickrema, P., Bonneux, B., Behera, I., Anson, B., Jacoby, E., Fung, A., Adhikary, S., Bhaumik, A., and Carbajo, R.J. (2023). Structural and mechanistic insights into the inhibition of Respiratory Syncytial Virus polymerase by a non-nucleoside inhibitor. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-05451-4"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2675","article-title":"Conventional and unconventional mechanisms for capping viral mRNA","volume":"10","author":"Decroly","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7786","DOI":"10.1128\/JVI.00530-15","article-title":"Respiratory Syncytial Virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter","volume":"89","author":"Noton","year":"2015","journal-title":"J. Virol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1128\/AAC.02540-14","article-title":"Characterization of a Respiratory Syncytial Virus L protein inhibitor","volume":"58","author":"Aschenbrenner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jac\/dky415","article-title":"Respiratory Syncytial Virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans","volume":"74","author":"Patel","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.jmb.2013.03.034","article-title":"Role of motif B loop in allosteric regulation of RNA-dependent RNA polymerization activity","volume":"425","author":"Garriga","year":"2013","journal-title":"J. Mol. Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.virol.2014.05.032","article-title":"Factors affecting de novo RNA synthesis and back-priming by the Respiratory Syncytial Virus polymerase","volume":"462\u2013463","author":"Noton","year":"2014","journal-title":"Virology"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Deval, J., Fung, A., Stevens, S.K., Jordan, P.C., Gromova, T., Taylor, J.S., Hong, J., Meng, J., Wang, G., and Dyatkina, N. (2016). Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154097"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1126\/science.adp2362","article-title":"Mutating a flexible region of the RSV F protein can stabilize the prefusion conformation","volume":"385","author":"Liang","year":"2024","journal-title":"Science"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:44:00Z","timestamp":1760031840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":152,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["v17060793"],"URL":"https:\/\/doi.org\/10.3390\/v17060793","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}